Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Other Non-Current Assets: 2010-2025

Historic Other Non-Current Assets for Myriad Genetics (MYGN) over the last 11 years, with Sep 2025 value amounting to $6.6 million.

  • Myriad Genetics' Other Non-Current Assets fell 60.00% to $6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.6 million, marking a year-over-year decrease of 60.00%. This contributed to the annual value of $8.5 million for FY2024, which is 44.81% down from last year.
  • Myriad Genetics' Other Non-Current Assets amounted to $6.6 million in Q3 2025, which was down 7.04% from $7.1 million recorded in Q2 2025.
  • In the past 5 years, Myriad Genetics' Other Non-Current Assets registered a high of $225.7 million during Q2 2021, and its lowest value of $3.6 million during Q1 2021.
  • For the 3-year period, Myriad Genetics' Other Non-Current Assets averaged around $13.4 million, with its median value being $14.9 million (2024).
  • In the last 5 years, Myriad Genetics' Other Non-Current Assets skyrocketed by 566.67% in 2021 and then tumbled by 96.10% in 2022.
  • Myriad Genetics' Other Non-Current Assets (Quarterly) stood at $8.3 million in 2021, then spiked by 86.75% to $15.5 million in 2022, then fell by 0.65% to $15.4 million in 2023, then plummeted by 44.81% to $8.5 million in 2024, then crashed by 60.00% to $6.6 million in 2025.
  • Its Other Non-Current Assets was $6.6 million in Q3 2025, compared to $7.1 million in Q2 2025 and $7.7 million in Q1 2025.